The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Guillain-Barre Syndrome Drugs Market Expected To Scale Between 2026 And 2030?
The guillain-barre syndrome drugs market size has experienced significant growth over recent years. It is anticipated to expand from $1.25 billion in 2025 to $1.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. The expansion observed historically can be attributed to the proven clinical effectiveness of IVIG therapy, the sustained utilization of plasma exchange in various neurological disorders, the presence of corticosteroids for managing symptoms, the increase in hospital neurology departments, and the enhanced recognition of GBS as a critical medical emergency.
The guillain-barre syndrome drugs market is anticipated to experience significant expansion over the coming years. It is projected to reach $1.73 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This growth during the forecast period is attributable to a rising incidence of autoimmune neurological disorders, heightened awareness of post-infectious gbs cases, improved access to advanced hospital care, an increase in IVIG manufacturing capacity, and a demand for rapid immune-modulating therapies in acute care settings. Prominent trends within this period encompass the sustained reliance on intravenous immunoglobulin as a first-line therapy, an increasing application of plasma exchange in severe guillain-barre cases, a stronger emphasis on early diagnosis and prompt treatment initiation, a growing need for hospital-based intensive gbs management, and the steady utilization of supportive and adjunctive drug therapies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15581&type=smp
What Factors Are Contributing To The Growth Of The Guillain-Barre Syndrome Drugs Market?
The increasing need for individualized medical care is anticipated to boost the Guillain-Barré syndrome drugs market in the future. Personalized medicine involves customizing medical treatment based on an individual’s genetic makeup, biomarkers, or lifestyle factors to enhance therapeutic effectiveness and reduce adverse effects. The rising demand for this approach is driven by advancements in genomics, increasing disease complexity, improved diagnostic technologies, and strong regulatory support. The Guillain-Barré syndrome drugs market benefits from personalized medicine by enabling tailored treatment plans that improve patient outcomes and reduce complications associated with generalized therapies. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, stated that the U.S. Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, which is considerably more than the six therapies approved in 2022. Therefore, the growing demand for personalized medicine is a significant factor propelling the growth of the Guillain-Barré syndrome drugs market.
How Is The Guillain-Barre Syndrome Drugs Market Categorized Across Its Segment Groups?
The guillain-barre syndrome drugs market covered in this report is segmented –
1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange
2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment
3) By Application: Clinic, Hospital, Other Applications
Subsegments:
1) By Immunoglobulins (Ivig): Intravenous Immunoglobulin (Ivig) Therapy, Human Normal Immunoglobulin (Hnig), Hyperimmune Immunoglobulin Products, Ivig Formulations For GBS Treatment
2) By Corticosteroids: Methylprednisolone, Prednisolone, Dexamethasone, Hydrocortisone, Betamethasone
3) By Plasma Exchange: Therapeutic Plasma Exchange (TPE), Plasmapheresis
What Trends Are Affecting The Growth Of The Guillain-Barre Syndrome Drugs Market?
Leading enterprises within the Guillain-Barré syndrome (GBS) drugs market are prioritizing the creation of advanced products, including humanized monoclonal antibodies, to boost treatment accuracy, mitigate immune-related nerve damage, and fortify their market standing. These antibodies are laboratory-engineered, predominantly featuring human antibody sequences, with a minor part originating from mouse or rat monoclonal antibodies; their purpose is to pinpoint particular immune components implicated in GBS pathology and to restrict complement-mediated inflammation. As an illustration, in October 2023, Annexon Inc., a clinical-stage biopharmaceutical firm based in the US, disclosed that both the European Medicines Agency and the U.S. Food and Drug Administration had awarded orphan drug designation to ANX005. This particular humanized monoclonal antibody works by selectively inhibiting C1q, thereby preventing complement-driven neuronal injury associated with GBS. Furthermore, the company confirmed the successful completion of target enrollment for its Phase 3 trial, with initial results anticipated in the first half of 2024. This development underscores ANX005’s prospective ability to swiftly arrest autoimmune damage and facilitate muscle strength recovery in individuals suffering from the condition.
Which Firms Are Influencing Competition In The Guillain-Barre Syndrome Drugs Market?
Major companies operating in the guillain-barre syndrome drugs market are CSL Behring LLC, Grifols SA, Octapharma AG, Takeda Pharmaceutical Company Limited, Biotest AG, Kedrion Biopharma Inc., Alexion Pharmaceuticals Inc., Argenx SE, Annexon Inc., Hansa Medical AB, F. Hoffmann-La Roche Ltd., Novartis AG, AbbVie Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Cadila Healthcare Limited, Akari Therapeutics Plc, Cellenkos Inc., Regenesance BV, Cresence AS
Get The Full Guillain-Barre Syndrome Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-drugs-global-market-report
Which Region Leads The Guillain-Barre Syndrome Drugs Market In Terms Of Market Share?
North America was the largest region in the guillain-barre syndrome drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Guillain-Barre Syndrome Drugs Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-drugs-global-market-report
Browse Through More Reports Similar to the Global Guillain-Barre Syndrome Drugs Market 2026, By The Business Research Company
Guillain Barre Syndrome Market Report 2026
https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report
Central Nervous System Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report
Neurological Disorder Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model